HCL, Oracle Health Sciences collaborate to accelerate digital clinical trials

HCL Technologies (HCL), recognized as a Platinum-Level member of Oracle Partner Network (OPN), and Oracle Health Sciences have inked a collaboration to help life sciences companies execute and scale the next generation of digital clinical trials to reduce the time and cost of drug development.

The collaboration includes the availability of HCL’s Faster Intelligent Trials (FIT) Solution using Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud).

HCL has said in its press statement that its FIT solution can be leveraged for a number of use cases, including improving patient engagement, collecting patient-reported outcomes, monitoring patient safety, improving medication adherence, or conducting e-visits during clinical trials to reduce patient and site burden.

According to HCL, the solution can also be applied for drugs already launched commercially, such as for remote patient monitoring, gathering real-world evidence, or as an accompanying application for digital therapies.

Shrikanth Shetty, Executive Vice President and North America Business Head for Life Sciences and Healthcare at HCL, said, “Although many of our customers have already established a strong case for leveraging mHealth technologies in clinical trials or digital therapies through proof of concept, we still see a chasm between the potential and actual adoption at scale. As a strategic partner to a large number of life sciences companies, HCL offers a comprehensive portfolio of services to navigate the journey from concept to adoption and continues to support them through the operational support services during or beyond clinical trials.”

“The life sciences industry has a great opportunity to radically change the way we understand and interact with patients during clinical trials. The collaboration between Oracle Health Sciences and HCL enables clinical teams to establish digitally-enabled clinical trial processes and new digital trial methods such as remote patient monitoring. This is a very exciting time for the pharma industry as new technologies such as mHealth continue to accelerate clinical trials and speed time to market for patients who are waiting,” said Jim Streeter, Global Vice President, Product Strategy, for Oracle Health Sciences.

The portfolio of mHealth services offered by the HCL and Oracle collaboration will help clients across different phases of their journey for the adoption of mHealth technologies. Those looking to establish a business case or roadmap can engage HCL and Oracle for a six- to eight-week “Proof of Value” package.

The statement also indicates that the companies that have more advanced mHealth initiatives can leverage the HCL FIT solution using Oracle mHealth Cloud 'as a service' for a specific clinical trial. HCL also provides implementation services for clients looking to adopt Oracle mHealth Cloud as an enterprise platform across all mHealth initiatives. HCL further helps the clients scale the operations by providing managed services for supporting stakeholders engaged in the clinical trials, including patients and investigators across global trial locations.

HCL offers a comprehensive portfolio of services to support clients throughout the clinical trial lifecycle, including business process redefinition, study setup, patient concierge, global device provisioning/kitting, multilingual support, customization, or building trial-specific applications.

In addition, there are core implementation services around Oracle mHealth Cloud, Oracle Health Sciences InForm Cloud, Oracle Health Sciences Trial Management and Monitoring Cloud, Oracle Health Sciences Data Management Workbench Cloud, and other required components in an Oracle Cloud service to ensure trials are executed as efficiently as possible.

HCL has the experience of supporting approximately 50,000 studies over 172,000 sites globally. On an annual basis, its support centers handle 400,000 requests from sites, investigators, nurses, and subjects for clinical trials sponsored by large global pharmaceutical companies as well as small biotech or medical devices companies.